Please ensure Javascript is enabled for purposes of website accessibility

Why Express, Roku, and Insys Therapeutics Slumped Today

By Dan Caplinger – Updated Apr 13, 2019 at 10:16AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Find out what made these stocks miss another rally in the broader market.

The stock market has been moving sharply higher lately, and Wednesday was no exception. A 0.6% gain for the Dow Jones Industrial Average matched well with similar-sized jumps in other major indexes, with investors taking comfort from encouraging readings on the macroeconomic front. Yet even though much of the market continued to build on gains from earlier in the week, some stocks weren't able to participate in the rally. Express (EXPR -2.65%), Roku (ROKU -1.66%), and Insys Therapeutics (INSY) were among the worst performers. Here's why they did so poorly.

Express looks a bit shabby

Shares of Express dropped 10% following the apparel retailer's release of its fourth-quarter financial results. Express said that revenue fell 10% from year-ago levels, due in large part to a decline of 6% in comparable sales during the period. A portion of the decline stemmed from the fact that there was one less week in the period, but the need for more generous promotions to move merchandise hurt the company's margin levels. Express also expects further deterioration in the coming quarter, including a comparable-sales plunge of 9% to 11%. With the retailer choosing not to give full-year 2019 guidance given uncertain trends and the absence of a permanent CEO, Express shareholders seem even more nervous than they did in December about whether the company has fallen out of fashion for good.

Black card with Express logo on it.

Image source: Express.

Did Roku fly too high?

Roku's stock dropped 14% after the smart TV specialist got some negative comments from stock analysts. Macquarie downgraded the stock from outperform to neutral, while Loop Capital went further, taking it from hold to sell. After huge gains so far in 2019, Roku's shares have already reflected much of the upside potential in the company's business, and some fear that copycat providers will eventually be able to challenge the early success that Roku has enjoyed. If it can successfully move from relying solely on hardware to gain customers for its streaming service, then Roku's upside could remain fully intact.

Check out the latest earnings call transcript for Express, Roku, and Insys Therapeutics.

Insys deals with big doubts

Finally, shares of Insys Therapeutics plunged 25%. The maker of opioid-based treatments said that an auditor has expressed negative views about whether Insys can continue to operate as a going concern, which is essentially accounting language for staying in business. With accusations that company executives paid bribes to boost prescription volumes for its cancer pain treatment Subsys, the roughly $100 million in cash on Insys' balance sheet might be insufficient to handle rising legal fees, settlements, and other costs. Until those questions get resolved, Insys will have trouble building confidence among its shareholders.

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Express, Inc. Stock Quote
Express, Inc.
EXPR
$1.10 (-2.65%) $0.03
INSYS Therapeutics Stock Quote
INSYS Therapeutics
INSY
Roku Stock Quote
Roku
ROKU
$59.88 (-1.66%) $-1.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.